Essential thrombocytosis: Difference between revisions
(Text replacement - "* " to "*") |
|||
| Line 6: | Line 6: | ||
==Clinical Features== | ==Clinical Features== | ||
* Leukocytosis | *Leukocytosis | ||
* Anemia | *Anemia | ||
* Splenomegaly | *Splenomegaly | ||
* Clotting or bleeding | *Clotting or bleeding | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
Revision as of 19:59, 10 July 2017
Background
- Rare, chronic myeloproliferative neoplasm
- Abnormal proliferation is seen in megakaryocytic line only
- Typically in elderly
- Generally asymptomatic
Clinical Features
- Leukocytosis
- Anemia
- Splenomegaly
- Clotting or bleeding
Differential Diagnosis
Evaluation
Workup
- CBC
- Chem 7
- ESR
- Bone marrow biopsy sometimes needed
Evaluation[1]
Per the WHO guidelines, diagnosis of ET requires all of the following:
| Major criteria |
|---|
| Thrombocytosis ≥ 450 x 109L |
| Megakaryocyte proliferation with little to no granulocyte or erythroid proliferation |
| Not meeting criteria for CML, PV, PMF, MDS or other myeloid neoplasm |
| No evidence of reactive thrombocytosis or presence of JAK2V617F or other clonal marker |
Management
- ASA 81mg
- Myelosuppressive agents (hydroxyurea, interferon alpha)
- Anagrelide
Disposition
Also See
References
- ↑ Tefferi, A, et al. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009; 115(17):3842-7,